Cited 1 times in

Comparison of 3-Year Clinical Outcomes Between Resolute™ Zotarolimus- and Sirolimus-Eluting Stents for Long Coronary Artery Stenosis

Title
Comparison of 3-Year Clinical Outcomes Between Resolute™ Zotarolimus- and Sirolimus-Eluting Stents for Long Coronary Artery Stenosis
Authors
EUI IM;BYEONG-KEUK KIM;MYEONG-KI HONG;YANGSOO JANG;DONGHOON CHOI;JUNG-SUN KIM;DONG-HO SHIN;HYUN HEE CHOI;AE-YOUNG HER;YOUNG-GUK KO
Issue Date
2013
Journal Title
Journal of Interventional Cardiology
ISSN
0896-4327
Citation
Journal of Interventional Cardiology, Vol.26(4) : 378~383, 2013
Abstract
OBJECTIVES: Long-term clinical outcomes were evaluated in long coronary artery stenosis treated with different types of drug-eluting stents. BACKGROUND: Long-term follow-up data to compare clinical outcomes between Resolute™ zotarolimus-eluting stent (R-ZES) versus sirolimus-eluting stent (SES) implantation for long coronary artery stenosis is insufficient. METHODS: A total of 254 patients (307 lesions) treated with R-ZES and 265 patients (303 lesions) treated with SES for long coronary lesions (total stent length ≥ 30 mm) were enrolled, and long-term (3 years) clinical outcomes were compared between the 2 groups. Efficacy (target lesion revascularization [TLR]) and safety (the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis) were assessed. RESULTS: The 2 groups had similar baseline characteristics except for the duration of dual antiplatelet therapy (23.4 ± 11.2 months in R-ZES-treated patients vs. 27.4 ± 13.9 months in SES-treated patients, P<0.001). Total stent length was similar in R-ZES-treated patients (45.0 ± 19.0 mm) and SES-treated patients (45.4 ± 18.6 mm) (P=0.464). The cumulative TLR rate was 4.6% in R-ZES-treated patients versus 4.6% in SES-treated patients (P=0.911). For safety parameters, R-ZES-treated patients showed a significantly lower rate of the composite occurrence of cardiovascular death, target lesion-related myocardial infarction, or target lesion-related definite stent thrombosis than SES-treated patients (0.4% vs. 2.4%, P=0.042). Particularly, the occurrence of target lesion-related definite stent thrombosis was significantly lower in R-ZES-treated patients than in SES-treated patients (0.0% vs. 2.0%, P=0.028). CONCLUSIONS: R-ZES stents showed superior long-term safety than SES for treating long coronary lesions, while maintaining a similar clinical efficacy.
URI
http://onlinelibrary.wiley.com/doi/10.1111/joic.12047/abstract

http://ir.ymlib.yonsei.ac.kr/handle/22282913/87322
DOI
10.1111/joic.12047
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse